Background
Materials and methods
Subjects
Angiography data and frame counting
Demographics and laboratory measurements
Statistical analysis
Results
Baseline characteristics
NCSF group (n = 55) | CSF group (n = 71) | p | |
---|---|---|---|
Age | 55.73 ± 11.93 | 55.85 ± 11.06 | 0.954 |
Male | 34 (61.8%) | 60 (84.5%) | 0.004 |
BMI | 26.29 ± 4.97 | 27.15 ± 3.41 | 0.251 |
Smoking history | 24 (43.6%) | 45 (63.4%) | 0.021 |
Anti-platelet drugs | 30 (54.5%) | 36 (50.7%) | 0.402 |
β-blockers | 19 (34.5%) | 23 (32.4%) | 0.474 |
ACE inhibitors | 6 (10.9%) | 5 (7%) | 0.326 |
ARBs | 8 (14.5%) | 10 (14.1%) | 0.569 |
Statins | 26 (47.3%) | 31 (43.7%) | 0.411 |
Hypertension | 36 (65.5%) | 42 (59.2%) | 0.296 |
Diabetes | 13 (23.6%) | 10 (14.1%) | 0.276 |
LVEF | 64.11 ± 4.20 | 48.68 ± 4.16 | 0.264 |
LVEDd | 48.44 ± 4.33 | 48.68 ± 4.16 | 0.753 |
CAE in LAD (%) | 29 (52.7%) | 52 (73.2%) | 0.044 |
CAE in LCX (%) | 14 (25.5%) | 41 (57.7%) | 0.001 |
CAE in RCA (%) | 31 (56.4%) | 52 (73.2%) | 0.111 |
CAE in 1 vessel | 33 (60%) | 21 (29.6%) | 0.001 |
CAE in 2 vessels | 15 (27.3%) | 26 (36.6%) | 0.001 |
CAE in 3 vessels | 7 (12.7%) | 24 (33.8%) | 0.001 |
NCSF group (n = 55) | CSF group (n = 71) | p | |
---|---|---|---|
LAD diameter (mm) | 5.52 ± 1.33 | 6.27 ± 1.25 | 0.002 |
LCX diameter (mm) | 5.05 ± 1.45 | 5.91 ± 1.39 | 0.001 |
RCA diameter (mm) | 5.91 ± 1.55 | 6.37 ± 2.02 | 0.173 |
Mean D | 5.18 ± 0.91 | 5.50 ± 0.85 | < 0.001 |
LAD CTFC | 20 (15–24) | 29 (22.75–34) | < 0.001 |
LCX CTFC | 21 (17–24) | 32 (25.75–38) | < 0.001 |
RCA CTFC | 19 (14–23) | 29 (23.5–35.25) | < 0.001 |
Mean CTFC | 19.29 (17.45–23.06) | 29.55 (24.7–34.05) | < 0.001 |
WBC | 6.36 ± 1.61 | 6.60 ± 1.58 | 0.399 |
Neutrophils | 3.75 ± 1.15 | 4.11 ± 1.22 | 0.091 |
Lymphocytes | 2.08 ± 0.60 | 1.88 ± 0.69 | 0.08 |
Monocytes | 0.37 ± 0.11 | 0.41 ± 0.13 | 0.064 |
NLR | 1.89 ± 0.58 | 2.08 (1.68–3.21) | 0.001 |
NPR | 0.0088 ± 0.0033 | 0.030 ± 0.157 | 0.317 |
LMR | 5.96 ± 1.75 | 4.81 ± 1.66 | < 0.001 |
hsCRP | 1.53 ± 1.67 | 1.98 ± 2.26 | 0.218 |
CRP | 2.65 ± 2.16 | 3.33 ± 3.34 | 0.192 |
HGB | 147.82 ± 14.46 | 152.15 ± 14.48 | 0.098 |
ALB | 45.69 ± 4.11 | 44.13 ± 4.10 | 0.036 |
URIC | 329.15 ± 79.71 | 370.78 ± 109.79 | 0.019 |
HbA1C | 6.27 ± 1.21 | 6.12 ± 1.08 | 0.469 |
Fasting Glucose | 6.332.13 | 5.79 ± 2.03 | 0.152 |
TG | 1.81 ± 1.12 | 1.93 ± 1.59 | 0.653 |
TC | 4.46 ± 1.08 | 4.50 ± 1.16 | 0.820 |
HDL-C | 1.18 ± 0.34 | 1.20 ± 0.38 | 0.704 |
LDL-C | 2.74 ± 0.91 | 2.74 ± 0.95 | 0.970 |
eGFR | 103.65 ± 32.28 | 102.09 ± 25.30 | 0.762 |
NT-proBNP | 114.53 ± 143.88 | 142.57 ± 196.85 | 0.419 |
Predictors of CSF
Variable | r | p |
---|---|---|
Gender | − 0.265 | 0.003 |
Smoking history | 0.2 | 0.026 |
LAD diameter (mm) | 0.297 | < 0.001 |
LCX diameter (mm) | 0.218 | 0.016 |
RCA diameter (mm) | 0.235 | 0.01 |
Mean D (mm) | 0.337 | < 0.001 |
NLR | 0.245 | 0.009 |
LMR | − 0.21 | 0.026 |
URIC | 0.218 | 0.021 |
ALB | − 0.187 | 0.036 |
Variables | Univariable | Multivariable | ||
---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | |
Male | 3.369 (1.451–7.820) | 0.005 | 1.601 (0.443–5.781) | 0.437 |
Smoking history | 2.236 (0.218–0.918) | 0.028 | 1.478 (0.505–4.324) | 0.476 |
LAD diameter | 1.584 (1.169–2.147) | 0.003 | ||
LCX diameter | 1.531 (1.169–2.005) | 0.002 | ||
Mean diameter of coronary arteries | 2.62 (1.543–4.117) | < 0.001 | 2.634 (1.54–4.51) | < 0.001 |
URIC | 1.005 (1.001–1.009) | 0.023 | 1.006 (1.001–1.012) | 0.018 |
NLR | 2.18 (1.321–3.599) | 0.002 | 1.741 (0.854–3.549) | 0.127 |
LMR | 0.67 (0.530–0.847) | 0.001 | 0.614 (0.464–0.814) | 0.001 |
ALB | 0.911 (0.833–0.995) | 0.039 | 0.917 (0.826–1.019) | 0.107 |